Scientific publications
-
Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), A Long-acting Amylin Analog
-
Dapiglutide is a dual agonist on human GLP-1- and GLP-2-receptors with a biased and prolonged signaling profile at the GLP-1R
-
Petrelintide (ZP8396) selectively reduces intake of high fat diet in DIO rats
-
Petrelintide (ZP8396) significantly reduces fat mass while preserving lean mass in DIO rats
-
Novel once-weekly amylin analog petrelintide (ZP8396) is well tolerated with improved GI tolerability after multiple dosing
-
Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
-
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
-
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
-
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
-
Safety, Tolerability, and Clinical Effects of ZP8396, an Amylin Analog: Multiple Ascending Dose Trial
